The aim of the study is the early and non-invasive diagnosis of lung cancer in patients with pulmonary ground glass opacity. In particular, objective of the study is to evaluate the presence or absence of circulating tumor DNA (ctDNA) on the peripheral blood of patients with evidence of ground glass opacity(GGO) at CT scan and to evaluate the role that this can play in the diagnostic / therapeutic process. The ctDNA evaluation will be performed at the first radiological finding and subsequently correlated with the malignancy of the lesion based on the radiological / histological criteria regularly used in international protocols. Secondary objective is the correlation, in patients with malignant GGO undergoing surgical treatment, of the ctDNA presence and tumor spread through the air spaces (STAS), and its correlation with local relapses.
Study Type
OBSERVATIONAL
Enrollment
80
Quantification of the circulating free DNA and the presence of targeted circulating tumor DNA
Thoracic Surgery Unit, Sapienza University of Rome
Roma, Italy
RECRUITINGQuantification of cf DNA
Assess quantity of the circulating free DNA measured in ng/μL using Qubit 2.0
Time frame: through study completion, an average of 2 year
Presence of ct DNA
Number of participants with of circulating tumor DNA using a lung pannel for genes: EGFR, KRAS, NRAS, TP53, SKT11, DDR2, PIK3CA, FGFR3, CTNNB1, MET, BRAF, ERBB2, SMAD4, PTEN, AKT, FGFR2, ERBB4, NOTCH1, FGFR1, ALK, IDH1, HRAS, IDH2, PDGFRA, RET, ROS1
Time frame: through study completion, an average of 2 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.